VivoSeq
Immunology

HAE

0

Pipeline Programs↗

4

Active Trials↗

5

Companies Involved↗

HAE is an early-stage landscape with 0 programs across 5 companies. The most active players are Novo Nordisk, CSL Behring, Evgen Pharma.

Intelligence

Pipeline Metrics

Competitive Density

16/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

92/100

Attrition Rate

6/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Novo Nordisk logo

Novo Nordisk

0 programs

PreclinicalCSL Behring logo

CSL Behring

0 programs

PreclinicalE

Evgen Pharma

0 programs

PreclinicalB

BioCryst Pharmaceuticals

0 programs

PreclinicalA

ADARx Pharmaceuticals, Inc.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

18

clinical trials

Completed11 · 61%
Recruiting3 · 17%
Unknown status1 · 6%
Enrolling by invitation1 · 6%
Available1 · 6%
Terminated1 · 6%

Clinical Trials

Trial Activity

18 trials

Concordance Between the Measurement of Whole Blood Fibrinogen by the qLabs®FIB Analyzer and Its Measurement by Conventional Method (Clauss Fibrinogen) in the Context of Severe Postpartum Haemorrhage
Recruiting·AAssistance Publique - Hôpitaux de Paris·N/A·NCT06255002·70 enrolled
The Benefit in Terms of Improvement in Haemoglobin Level at 6 Months in Premature Babies Receiving Alternate Iron Substitution 4 Times a Week Compared to a Daily Substitution
Recruiting·—·N/A·NCT06624709·160 enrolled
STOP-HAE: A Phase 3 Study of ADX-324 in HAE
Recruiting·AADARx Pharmaceuticals, Inc.·Phase 3·NCT06960213·90 enrolled
Open-label Berotralstat Access to HAE Patients Previously Enrolled in Berotralstat Studies
Enrolling by invitation·BBioCryst Pharmaceuticals·Phase 3·NCT04933721·139 enrolled
Haemocomplettan® P During Aortic Replacement
Completed·CSL Behring logoCSL Behring·Phase 2·NCT00701142·80 enrolled
The Effect of Ischaemic-Reperfusion in Man - A Bradykinin Dependent Pathway
Completed·UUniversity of Edinburgh·N/A·NCT00965120·12 enrolled
Genotype Expression and Phenotype of Endothelial Cells, Carrying an ACVRL1, ENG or SMAD4 Mutation, in Response to BMP9 for the Identification of New Therapeutic Targets in Hereditary Haemorrhagic Telangiectasia
Completed·HHospices Civils de Lyon·N/A·NCT05632484·16 enrolled
Recombinant Factor VII for Intractable Postpartum Haemorrhage
Completed·—·N/A·NCT05298826·41 enrolled
SFX-01 After Subarachnoid Haemorrhage
Completed·EEvgen Pharma·Phase 2·NCT02614742·90 enrolled
Turoctocog Alfa in Haemophilic Italian Patients: Protection and Engagement in Recreational Activities
Completed·Novo Nordisk logoNovo Nordisk·N/A·NCT04584892·18 enrolled
The Effect of Hydroxyethylstarch 6% 130/0.4 in a Balanced Electrolyte Solution (Volulyte®) Compared to Gelatine (Geloplasma®) on Microvascular Reactivity and Tissue Oxygen Saturation During Haemodilution Measured With Near-infrared Spectroscopy
Completed·UUniversity Hospital, Ghent·N/A·NCT02034682·40 enrolled
Clinical Randomisation of an Antifibrinolytic in Significant Haemorrhage
Completed·LLondon School of Hygiene and Tropical Medicine·Phase 3·NCT00375258·20,211 enrolled
The Effects of DLBS1033 on Haemostasis Parameters in Healthy Volunteers
Completed·IIndonesia University·Phase 2·NCT01694537·21 enrolled
Non Substitutive Strategies to Improve Haemophilia Care in Developing Countries. Experience in Ivory Coast.
Completed·CCliniques universitaires Saint-Luc- Université Catholique de Louvain·N/A·NCT03054662·142 enrolled
NovoSeven® in Severe Postpartum Haemorrhage - Experiences From UK, DK, FR, NL
Completed·LLeiden University Medical Center·N/A·NCT04723979·3,322 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)